Posted by Michael Wonder on 14 Apr 2020
Drug evaluation during the COVID-19 pandemic
14 April 2020 - The search for a treatment for COVID-19 is testing our country’s ability to quickly develop, test, and deploy medications, presenting both opportunities and challenges to our drug-assessment apparatus.
Several aspects of the U.S. response raise serious concerns, highlighting how the processes for evaluating and approving drugs can go awry during a public health crisis.
The global pandemic has put pressure on clinicians and the FDA to act swiftly to make medications available to patients.
